Treatment of hormone refractory prostate cancer

Seminars in Urologic Oncology

Volumn 19, Issue 3, 2001, Pages 202-211

  Knox, J J ^a   Moore, M J ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Chemotherapy; Estramustine; Hormone refractory prostate cancer; Mitoxantrone

Indexed keywords

ANDROGEN; ANTHRACYCLINE ANTIBIOTIC AGENT; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ESTRAMUSTINE; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; HORMONE; HYDROCORTISONE; HYDROXYUREA; MEDROXYPROGESTERONE ACETATE; METHOTREXATE; MITOMYCIN C; MITOXANTRONE; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE; PREDNISONE; STRONTIUM 89; SURAMIN; UNINDEXED DRUG; VINBLASTINE; VINCA ALKALOID; VINCRISTINE;

AGE; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG INDUCED DISEASE; DRUG SENSITIVITY; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; MALE; META ANALYSIS; PERFORMANCE; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; REVIEW;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ESTRAMUSTINE; HUMANS; MALE; MITOXANTRONE; PAIN; PALLIATIVE CARE; PREDNISONE; PROSTATIC NEOPLASMS; QUALITY OF LIFE; SURAMIN;

EID: 0034867520     PISSN: 10810943     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Results of a randomized phase III trial to evaluate the efficacy of strontium-89 adjuvant to external beam irradiation in the management of endocrine resistant metastatic prostate cancer
2. Treatment of metastatic prostate cancer with low dose prednisone: Evaluation of pain and quality of life as pragmatic indices of response
3. Flutamide withdrawal syndrome: Its impact on clinical trials in hormone resistant prostate cancer
4. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer
5. Eligbility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the Prostate-Specific Antigen Working Group
6. Analysis of survival by tumor response
7. Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate?
8. A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma
9. Current chemotherapy and future directions in research for the treatment of advanced hormone-refractory prostate cancer
10. Chemotherapy programs of the national prostate cancer project (NPCP)
11. Adriamycin and cyclophosphamide versus hydroxyurea in advanced prostate cancer
12. Doxorubicin, mitomycin-C, and 5-fluorouracil (DMF) in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancer
13. Doxorubicin, mitomycin C and 5-fluorouracil in the treatment of hormone refractory adenocarcinoma of the prostate: A SWOG study
14. Chemotherapy for hormonally refractory advanced prostate carcinoma
15. Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer
16. Mitoxantrone: Modest activity in a phase II trial in advanced prostate cancer
17. Mitoxantrone a nontoxic, moderately active agent for hormone resistant prostate cancer
18. Chemotherapy with mitoxantrone plus prednisone or prednisone alone of symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative endpoints
19. Hydrocortisone with or without mitoxantrone in: Hormone-refractory prostate cancer: Results of the cancer and leukemia group B 9182 study
20. Phase III study of mitoxantrone/low-dose prednisone vs low-dose prednisone alone in patients with asymptomatic hormone-refractory carcinoma of the prostate
21. Mechanism based chemotherapy for prostate cancer
22. Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer
23. Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate
24. Comparison of estramustine phosphate, methotrexate and cis-platinum in patients with advanced, hormone refractory prostate cancer
25. A comparison of estramustine phosphate and streptozotocin in patients with advanced prostatic carcinoma who have had extensive irradiation
26. The use of estramustine and prednimustine versus prednimustine alone in advanced metastatic prostatic cancer patients who have received prior irradiation
27. Comparison of estramustine phosphate and vincristine alone or in combination for patients with advanced, hormone refractory, previously irradiated carcinoma of the prostate
28. A comparison of estramustine phosphate versus cis-platinum alone versus estramustine phosphate plus cis-platinum in patients with advanced hormone refractory prostate cancer who had had extensive irradiation to the pelvis or lumbosacral area
29. Comparison of flutamide and emcyt in hormone-refractory metastatic prostatic cancer
30. Mitomycin C versus estramustine in the treatment of hormone resistant metastatic prostate cancer: The final analysis of the EORTC genitourinary group prospective randomized phase III study (30865)
31. A randomized study on hormone-resistant prostatic cancer: Estramustine phosphate versus low dose epirubicin with or without medroxyprogesterone acetate
32. Epirubicin and medroxyprogesterone acetate versus estramustine phosphate in hormone-resistant prostatic cancer: A prospective randomized study
33. Estramustine and vinblastine: Use of prostatic specific antigen as a clinical trial end point for hormone refractory prostatic cancer
34. Estramustine and vinblastine for patients with progressive androgen-independent adenocarcinoma of the prostate
35. Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network Phase III trial
36. Report of an extended phase II trial of oral estramustine and oral etoposide in the treatment of hormone refractory prostate cancer patients
37. A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer
38. Oral estramustine and oral etoposide for hormone refractory prostate cancer
39. Phase II study of estramustine and vinorelbine in hormone refractory prostate carcinoma patients
40. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone refractory prostate cancer
41. Phase II study of weekly paclitaxel (P) by 1-hour infusion plus reduced-dose oral estramustine (EMP) in metastatic hormone-refractory prostate carcinoma (HRPC): A trial of the Eastern Cooperative Oncology Group
42. Phase II trial of oral estramustine, oral etoposide and IV paclitaxel in hormone refractory prostate cancer
43. Response and prelimunary survival results of a phase II study of docetaxel (D) + estramustine (E) in patients with androgen-independent prostate cancer
44. A phase II study of docetaxel, estramustine and low-dose hydrocortisone in men with hormone refractory prostate cancer: A final report of the CALGB 9780
45. Preliminary evaluation of a short course of estramustine phosphate and docetaxel in the treatment of hormone refractory prostate cancer
46. Docetaxel and estramustine versus mitoxantrone and prednisone for HRPC: Scientific basis and design of Southwest Oncology Group study 9916
47. Docetaxel (Taxotere) as monotherapy in the treatment of HRPC: Preliminary results
48. Phase II randomized trial of weekly Paclitaxel (Taxol) with or without estramustine phosphate in patients with symptomatic, hormone-refractory, metastatic carcinoma of the prostate (HRMCP)
49. Suramin, anticancer and angiosuppressive agent inhibits endothelial cell binding of basic fibroblast growth factor, migration, proliferation and induction of urokinase-type plasminogen activator
50. Suramin, a novel growth factor antagonist with activity in hormone refractory metastatic prostate cancer
51. Suramin, an active drug for prostate cancer: Interim observations in a phase I trial
52. Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer
53. Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: Results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone
54. Results of CALGB 9480, a phase III trial of 3 different doses of suramin for the treatment of hormone refratory prostate cancer (HRPC)
55. Expression of bcl-2 oncoprotein and p-53 protein accumulation in bone marrow metastases of androgen independent prostate cancer
56. Interim results of a phase III study of the matrix metalloprotease inhibitor prinomastat in patients having metastatic hormone refractory prostate cancer (HRPC)
57. The Endothelin-A receptor antagonist atrasentan (ABT-627) delays clinical progression in hormone refractory prostate cancer: A multinational, randomized, double-blind, placebo-controlled trial
58. Adjuvant therapy for clinical localized prostate cancer treated with surgery or irradiation